Skip to main content
Researchers compare effect of weight-loss drugs on cardiometabolic risk profile

A study in Gastroenterology showed that obese adults who received the weight-loss medications liraglutide, lorcaserin, naltrexone-bupropion, orlistat or phenterimine-topiramate had an average blood glucose reduction of 4.0 mg/dL and a drop in LDL cholesterol by a mean of 0.1 mg/dL. Researchers analyzed 28 randomized controlled trials involving 29,018 patients and found that these drugs also resulted in an almost 2 mmHg reduction in systolic and diastolic blood pressure and decreases in waist circumference that ranged from 2.3 cm to 7 cm among patients.

Full Story: